{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:31:46Z","timestamp":1785173506249,"version":"3.55.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Antibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection of targets for the development of antibody-drug conjugates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this article, we identified existing ADCs and their targets through clinical trial databases and public genomic datasets, performed differential analysis of tumor antigen targets (TATs) expression between tumor and normal tissues, and evaluated the necessity of the targets for tumor cell lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In gynecologic malignancies, we have identified several highly expressed TATs, some of which have been targeted by FDA-approved ADCs, such as TROP2 and Nectin-4, although these drugs have not been approved for the treatment of gynecologic cancers. At the same time, we also observed that some targets of ADCs that have not yet been approved by the FDA also show high expression levels in gynecologic malignancies tissues, such as MSLN, ERBB3, NaPi2b, etc. Furthermore, we identified TATs with high expression levels in various pathological subtypes of ovarian, endometrial, and cervical cancer. Notably, some TATs are crucial to the survival of tumor cells, such as CD71, TOP1, and TDGF1, which are essential for the survival of ovarian, endometrial, cervical, and other tumor cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We have innovatively predicted the potential targets of ADCs in treating gynecological malignancies and provided a new perspective on applying some FDA-approved ADCs in indications for gynecological cancers.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1525733","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:51:14Z","timestamp":1739947874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuance","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2159-8290.Cd-nb2023-0047","article-title":"HER2-Targeted therapy shows promise across tumor types","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/0008-5472.Can-21-3236","article-title":"Pathophysiologic and pharmacologic considerations to improve the design and application of antibody-drug conjugates","volume":"82","author":"Boghaert","year":"2022","journal-title":"Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/bjc.1983.4","article-title":"Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer","volume":"47","author":"Ford","year":"1983","journal-title":"Br. J. Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"107160","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"B13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/10600280221118370","article-title":"A review of Tisotumab vedotin-tftv in recurrent or metastatic cervical cancer","volume":"57","author":"Heitz","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1158\/1078-0432.Ccr-21-0194","article-title":"Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/pharmaceutics15082160","article-title":"Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload","volume":"15","author":"Kondrashov","year":"2023","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12864-019-5661-x","article-title":"Systematic identification and validation of the reference genes from 60 RNA-Seq libraries in the scallop Mizuhopecten yessoensis","volume":"20","author":"Li","year":"2019","journal-title":"BMC Genomics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/jco.23.02005","article-title":"Efficacy and safety of Trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in fr\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1329","DOI":"10.1002\/ctm2.1329","article-title":"Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates","volume":"13","author":"Nieto-Jim\u00e9nez","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12920-019-0514-7","article-title":"GENT2: an updated gene expression database for normal and tumor tissues","volume":"12","author":"Park","year":"2019","journal-title":"BMC Med. Genomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1535-7163.Mct-20-0014","article-title":"First-in-Human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"122676","DOI":"10.1016\/j.lfs.2024.122676","article-title":"Antibody-drug conjugates: principles and opportunities","volume":"347","author":"Phuna","year":"2024","journal-title":"Life Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1274088","DOI":"10.3389\/fphar.2023.1274088","article-title":"A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy","volume":"14","author":"Riccardi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1158\/1078-0432.Ccr-23-3414","article-title":"Antibody-drug conjugates: advancing from magic bullet to biological missile","volume":"30","author":"Veneziani","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1158\/1078-0432.Ccr-20-3119","article-title":"FDA approval summary: accelerated approval of Sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/d0cs00310g","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.13390\/j.issn.1672-1861.2024.05.001","article-title":"Immunotherapy and targeted therapy for advanced or recurrent\/metastatic cervical cancer","volume":"25","author":"Wang","year":"2024","journal-title":"Chin. J. Clin. Obstetrics Gynecol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.19401\/j.cnki.1007-3639.2023.11.001","article-title":"The latest progress and prospect of gynecological tumor treatment at 2023 ESMO","volume":"33","author":"Xia","year":"2023","journal-title":"China Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.19538\/j.fk2024050111","article-title":"Guidelines for the clinical application of antibody-drug conjugate for gynecological malignancies(2024 edition)","volume":"40","author":"Zhang","year":"2024","journal-title":"Chineses J. Pract. Gynecol. Obstetrics"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.16438\/j.0513-4870.2020-0325","article-title":"Consideration of antibody drug conjugates development and regulation","volume":"55","author":"Zhang","year":"2020","journal-title":"Consid. Antib. drug conjugates Dev. Regul."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1525733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:51:23Z","timestamp":1739947883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1525733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1525733"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1525733","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"article-number":"1525733"}}